COVID-19 - The vaccine miracle must include strictness and caution
Outside of SARS-CoV-2 vaccines, there is little positive outlook for the control of Covid-19 epidemic. Schematically, two antagonistic and extreme strategies have been proposed, zero-covid and herd immunity. Between the two, often oscillating measures, based on medical but also societal and political considerations, have been taken without any major effect on the course of the epidemic. Vaccines are a game-changer by providing a real opportunity to sustainably protect everyone against infection and eliminate the circulation of the virus. The Pfizer, Moderna and AstraZeneca vaccines, the three currently authorized in France, overall induce remarkable protection rates of 95 %, 94 % and 70 % respectively. The surprise came from that this efficacy was obtained after a rapid development, by targeting only the viral protein S as antigen, and by using the administration of expression vectors innovative in vaccinology, consisting of either messenger RNA or recombinant adenovirus. However, bringing the epidemic under control requires a well-organized mass vaccination campaign. It also requires careful monitoring of many parameters such as the occurrence of adverse events, duration of induced immunity, vaccine efficacy against emerging variants of SARS-CoV-2, interest or not of vaccinating people already infected, vaccination of immunocompromised patients. Vaccination must be accompanied by the maintenance of barrier measures and gestures and an amplification of clinical and biological investigations both to validate its effectiveness on the Covid-19 epidemic and to prepare for future developments in vaccinology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Virologie (Montrouge, France) - 25(2021), 3 vom: 01. Juni, Seite 141-147 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Covid-19 - Le miracle vaccinal doit inclure rigueur et prudence |
|---|
| Beteiligte Personen: |
Agut, Henri [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 16.07.2021 Date Revised 16.07.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1684/vir.2021.0903 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326605878 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326605878 | ||
| 003 | DE-627 | ||
| 005 | 20231225194945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1684/vir.2021.0903 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326605878 | ||
| 035 | |a (NLM)34112629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Agut, Henri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 - The vaccine miracle must include strictness and caution |
| 246 | 3 | 3 | |a Covid-19 - Le miracle vaccinal doit inclure rigueur et prudence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.07.2021 | ||
| 500 | |a Date Revised 16.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Outside of SARS-CoV-2 vaccines, there is little positive outlook for the control of Covid-19 epidemic. Schematically, two antagonistic and extreme strategies have been proposed, zero-covid and herd immunity. Between the two, often oscillating measures, based on medical but also societal and political considerations, have been taken without any major effect on the course of the epidemic. Vaccines are a game-changer by providing a real opportunity to sustainably protect everyone against infection and eliminate the circulation of the virus. The Pfizer, Moderna and AstraZeneca vaccines, the three currently authorized in France, overall induce remarkable protection rates of 95 %, 94 % and 70 % respectively. The surprise came from that this efficacy was obtained after a rapid development, by targeting only the viral protein S as antigen, and by using the administration of expression vectors innovative in vaccinology, consisting of either messenger RNA or recombinant adenovirus. However, bringing the epidemic under control requires a well-organized mass vaccination campaign. It also requires careful monitoring of many parameters such as the occurrence of adverse events, duration of induced immunity, vaccine efficacy against emerging variants of SARS-CoV-2, interest or not of vaccinating people already infected, vaccination of immunocompromised patients. Vaccination must be accompanied by the maintenance of barrier measures and gestures and an amplification of clinical and biological investigations both to validate its effectiveness on the Covid-19 epidemic and to prepare for future developments in vaccinology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a SARS-CoV-2 variant | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 4 | |a recombinant adenovirus vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Virologie (Montrouge, France) |d 1998 |g 25(2021), 3 vom: 01. Juni, Seite 141-147 |w (DE-627)NLM097406481 |x 1267-8694 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:3 |g day:01 |g month:06 |g pages:141-147 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/vir.2021.0903 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 3 |b 01 |c 06 |h 141-147 | ||